SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study – the BELCOMID study

• DOI: 10.3389/fimmu.2023.1126351
• Publication Date: 2023-03-01T06:16:30Z
• Authors: Jeroen Geldof; Marie Truyens; João Sabino; Marc Ferrante; Jo Lambert; Hilde Lapeere; Tom Hillary; An Van Laethem; Kurt de Vlam; Patrick Verschueren; Elizaveta Padalko; Triana Lobaton; Séverine Vermeire
• Keywords: COVID-19 Vaccines; real-world data; COVID19; SARS-CoV-2; Immunology; Vaccination; COVID-19; immunomodulator; RC581-607; Antibodies; 3. Good health; Cohort Studies; Immunomodulating Agents; Belgium; Medicine and Health Sciences; Blood Group Antigens; Immunology and Allergy; Humans; Prospective Studies; Immunologic diseases. Allergy; IMID; biologic

Background The risks and impact of COVID19 disease vaccination in patients with Immune Mediated Inflammatory Diseases (IMID) remain incompletely understood. IMID particularly receiving immunosuppressive treatment were excluded from the original, registrational phase-3 efficacy safety trials. Real-world observational data can help to fill this gap knowledge. BELCOMID study aims explore interaction between IMIDs, immune-modulating modalities SARS-CoV-2 infection a real-life patient cohort. Methods A multidisciplinary, prospective, cohort was set up. Consecutive IMIDs gut, joints skin followed at two high-volume referral centers invited. Both under conventional or targeted immune modulating therapies included. Patient serological samples collected 3 predefined periods (before vaccination, before booster after vaccination). Primary endpoints positive PCR-test serology reflecting previous vaccination. Associations modality activity assessed. Results first inclusion vaccination) are reported. At period assessed 2165 IMID-patients second period, 2065 whom 1547 had received complete baseline 222 partially vaccinated. rate remained low both groups. No significant increase flare-up noted prior infection. Multiple logistic regression analyses did not show influence IMID-treatment on risk (based PCR positivity N-serology). Patients treated immunomodulators, systemic steroids, advanced such as biologics small molecules, reduced S-antibody seroconversion. response also lower without active smokers. subset (4.1%) no S- nor N-antibody seroconversion following Conclusion results confirm benign course large IMID-population. However, our underscore need for repeated smoking cessation steroids during pandemic.